Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.80
-0.29 (-3.19%)
Apr 8, 2026, 11:44 AM EDT - Market open
Company Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Dec 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Ilya Rachman |
Contact Details
Address: 11400 West Olympic Boulevard, Suite 200 Los Angeles, California 90064 United States | |
| Phone | 310 651 8041 |
| Website | immixbio.com |
Stock Details
| Ticker Symbol | IMMX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 1873835 |
| CUSIP Number | 45258H106 |
| ISIN Number | US45258H1068 |
| Employer ID | 45-4869378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer and Head of Clinical Development |
| Sean Senn J.D., M.B.A., M.Sc. | Co-Founder |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder |
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy |
| Mel Davis-Pickett | Head of CMC Technical Development |
| Michael A. Grabow | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 6, 2026 | ARS | Filing |
| Apr 6, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 6, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 10-K/A | [Amend] Annual report |
| Mar 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 424B5 | Filing |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 20, 2026 | SCHEDULE 13G | Filing |